MBX Biosciences doses first patient in Phase 3 trial of canvuparatide for hypoparathyroidism
The trial, called oPTimize, will enroll about 160 adults and test the once-weekly PTH replacement therapy against placebo over 26 weeks.
SEC filing
Latest
4 stories
Thursday, August 27
Thursday, August 6
MBX Biosciences reports Q2 2026 results, canvuparatide Phase 3 recruiting
MBX posted one-year canvuparatide data, early MBX 4291 obesity results, and $418.6 million in cash expected to last into 2029.
SEC filing
Monday, July 13
MBX Biosciences registers Phase 3 trial of canvuparatide for hypoparathyroidism
MBX Biosciences names Steven Hoerter CEO as Kent Hawryluk departs
The company disclosed a leadership transition effective July 13, 2026, with CFO John Smither also elevated from interim to permanent status.
SEC filing